

#### 6th India Pharmaceutical Forum (IPF) 2021

#### Global View on Regulatory Affairs

#### Partnership for Progress in Patient Care

Babu KS Head – Regulatory Affairs, Pfizer Healthcare India

February 25th, 2021





This presentation does not necessarily represent the views or official position of the organization, Pfizer, or any of their subsidiaries, or leaders or employees or partners, but is solely based on <u>my personal thoughts, ideas, and opinions.</u>

- Babu KS




## Today's World

- VUCA Volatile, Uncertain, Complex & Ambiguous
- High potential for disruption
- Are we prepared to manage another pandemic?
- Can we predict or prevent another pandemic?

# Need of Today and Tomorrow:

**Unprecedented Collaborations & Partnerships** 





Partnership for Progress in Patient Care

#### Regulatory Agencies & Policy Makers



#### Increasing Convergence: EMA & US FDA

- Remarkable alignment
- 90% of MA Decisions for New Drugs  $\odot$
- Great focus on investment, intent, effort for the common goal (Patient Centricity)
- Mutual Recognition Act
- Joint inspections
- Exchange of Reports
- Batch Testing Waiver





### Successful Convergence of Regulatory Agencies: Nitrosamines

- International Strategic Group' led by Health Canada
- Members: HC, EMA, US FDA, MHLW, TGA, S-HSA, SwissMedic
- Well-coordinated efforts: Exchange of info, methods, datasets
- Outcome: Internationally-recognized "Acceptable Daily-Intake Limits"
- Collaboration to Conquer Common Challenges



## Recommendations: EMA Lessons Learnt Group

- Nitrosamines International Working Group Experience
- Create a Strategic Working Group for all future incidents, crises, challenges
- Exchange of commercially confidential information: Public Health Interests outweigh Confidentiality
- Increased International cooperation on GMPs; Information Exchange, Workload Sharing etc.
- International partnerships on the review of Toxicological Data Review, Risk Assessment; PV Data Review
- Common Procedures, Guidelines, Norms for Global Crisis Management
- ICMRA International Coalition of Medicines Regulatory Authorities



### Additional Areas of Convergence: HAs

- Real-time Regulatory Data Exchange
- Minimize duplicate testing (animal & human) across the world
- Regulatory Harmonization: Can this become a REALITY?
- One Global Dossier
- Drug Development data standards for complex / novel dosage forms
- Risk-based Approach (continue the Good Work!)
- Greater Efforts towards Pharmacopeial Convergence



#### Dossier Requirements: Regulated Markets vs Rest of World

- Regulatory Harmonization: Can this become a REALITY?
- One Global Dossier: Dream Desire Demand Destination (???)
- Leveraging Existing MA approvals, with minimal administrative data
- QbD vs Traditional Dev Approach
- Post-approval Change Mgmt through Harmonized Regulatory Tools/ Enablers
- Differences in License Maintenance / Renewal requirements (across HAs)
- Acceptable Customization: Zone-relevant Stability, Translations etc.

## Opportunities for Greater Convergence of HAs

- Dream: "Medicines for All across Globe" Challenges?
- International Data Stds by Global Reg Agencies: Set up & Adopt
- Developed vs ROW Markets: Lack of alignment in regulatory framework / systems / preparedness
- Differences in License Maintenance / Renewal Reqts. (across HAs)
- Greater Mutual Recognition Efforts; keeping ROW Markets in mind
- Harmonization of Clinical Trial Stds. / Reqts. where possible
- Balanced approach in recognizing Global Clinical Trial Data for Critical Care products & products for Emergency Use
- Global Data Standards for Novel Emerging Technologies; can we help adoption by all HAs?

Partnership for Progress in Patient Care





#### **Collaboration with Competitors**

#### COVID-19 Vaccine Maker Pledge

We fire undersigned beging handlick at unspects, and the index data as indexing to hold the data and approperturbing particular as index for 1 (MU 111 as and and and with high orbital bandlicks and used clarify processors).

This show and obtains of instrum, tracking any particular sequence to 2000 K. In a momentum data metal the signal registration approximation and the signal registration and an an attract the association of the tracking of these statements and the proceeding and the type field as a statement of the particular for the association of the the association of the control of the association of the the association of the control of the association of the association of the control of the association of the association of the control of the association of the association of the control of the association of the association of the observation of the association of the association explicit of the association of the association of the association of the Ad as and the ad of the association of the association of the Ad as an association of the association of the association to the Ad as an association of the association of the association of the Ad as an association of the association of the association of the Ad as an association of the association of the association method of the administration of the association of the association of the Ad as an association of the association of the administration of the association of approximation of the association of the association of the Ad as an association of the association of the association of the association of approximation of the association of the associati

Advantage publicate from anyonic regulatory authorities such as the first inspecting the distinguishest of (2010) of sections, consider with restring standards, and any from points from manifest departic bandless.

Arrest frain the safety and self losing all contracted individuals are ingrated

Continue to advant to high scientify and related mentants requesting the contact of drives their and the signs of manufacturing processes.

Units subset for approval in interprets set authorization when interest study that is improved and interpret a flow in interest study that is improved and contained to make support models of support approperturbation of support and to flow.

Note to process of from copies and range of vacing aptions, including from collabor to photo access.

We believe this procipy will help essure public proficience in the Apresian scientific, and exploiting presents by which (2003): 13 year time are evaluated and may affinishing be approved.



#### 10 Pharma Giants, 1 Pledge, 1 Purpose

#### We Stand With Science

"Today, Pfizer and several other leading biopharmaceutical companies are sending a clear and united message that we will not compromise the integrity of science nor the scientific process as we each move forward with urgency to deliver safe and effective vaccines that we hope will change the course of this pandemic."

Albert Bourla, Chairman and CEO






### Industry Collaborations

- IPA leading the Collaborations in Indian Pharma Industry
- Asset-based Collaborations (business-focused) to Service-based (cause-focused)
- Pfizer & BioNTech Co-development of Covid-19 vaccine
- Novartis & Sanofi Leveraging the manufacturing capabilities for Pfizer Vaccine
- ICON plc. Clinical Trial services for Pfizer Vaccine
- Global Logistics Partners for Supply Chain / Distribution
- AZ & University of Oxford
- Moderna & National Institute of Allergy & Infectious Diseases
- Bharath Biotech & Indian Council of Medical Research (ICMR)
- Pfizer's support to Gilead in Remdesivir manufacturing

HCQ Supplies from India to the World Global Product Development – Global Regulatory Affairs

#### Additional Industry-Agency Partnership Opportunities

- Tech Revolutions are faster than Regulatory Revisions
- Novel Methods, Novel Technologies, Novel theories
- Al-based evaluations, Robotic Process Automation, Digital Pills
- Rule Book becomes Obsolete and Irrelevant in no time
- Help HAs catch up with "Speed of Science"
- Industry-HA Partnerships : Most Crucial
- Connect with Regulators Proactively



- FDA's Innovation Challenge: Alternatives to Ethylene Oxide Sterilization
- Are academic institutes catching up with the speed? Edu. Reforms (Industry Responsibility; another partnership opportunity)

## Lessons from COVID-19 Vaccine EUA

- EUA within a year
- Rolling Review (MHRA, EU, HC) Expediting Approval Process
- Risk-based approach
- Crisis brings out the Best: Can this be the new normal?
- COVID-19 Vaccine Success Story must continue:

Why not: Cancer, Alzheimer's, Muscular Dystrophy etc.

• Key to Success:

Partnerships across Health Agencies-Industry-Academia-Research Organizations

## Last Words... The India Advantage!

- Strong Chemistry foundation (Powerhouse for API Technology)
- Research & Dev Competence (Novel / Complex Formulations)
- Manufacturing Infrastructure & Capabilities
- Deep Regulatory understanding & Compliance Mindset
- Strong & Conducive Ecosystem (Associations, Regulators etc.)
- Scientific & Technical Educational System
- Information Technology as a backbone
- Collaborative Spirit & Global Mindset



# THANK YOU

Babu KS Head – Regulatory Affairs, Pfizer Healthcare India Pvt Ltd Mail: <u>babu.ks@Pfizer.com</u> Cell: +91-8754502930

